BioMarin reports record FY2023 revenue $2.42B (+15% YoY); non-GAAP EPS $2.08 (+36% YoY)

BIOMARIN PHARMACEUTICAL INC

2023-FY EPS reported $0.87 revenue$2,419,226,000

FY2023 total revenues $2.42B (+15% YoY); GAAP diluted EPS $0.87 (+16% YoY); non-GAAP diluted EPS $2.08 (+36% YoY).
VOXZOGO net revenues $146M in Q4'23 (+118% Q/Q) and $470M for FY'23 (+178% YoY); 2,613 children treated at year-end.
Q4'23 total revenues $646.2M (+20% YoY); GAAP net income $20.4M vs $0.2M loss in Q4'22.
2024 guidance: double-digit total revenue growth, non-GAAP operating margin expansion, EPS growing faster than revenue.
FDA approved VOXZOGO for children under 5; ~70% of new US starts from that age group in Q4'23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

BIOMARIN PHARMACEUTICAL INC reported fourth quarter and full year ended December 31, 2023 results: revenue $646.2 million, net income $20.4 million, EPS $0.11. Guidance reaffirmed.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $646.2 million
Net income: $20.4 million
EPS: $0.11
Guidance: reaffirmed
Result: reported results

Exact text from the filing

plans and convertible debt in periods when they are dilutive under Non-GAAP. nm Not meaningful Financial Highlights: • Total Revenues for the fourth quarter of 2023 were $646.2 million, an increase of 20% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to higher VOXZOGO sales volume driven by new patients initiating

View on SEC.gov

Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-24-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.